UW Medicine Launches Clinical Trial of CNP-103 to Preserve Insulin Production in Type 1 Diabetes
核心洞察
UW Medicine (搜索) researchers are recruiting adults aged 18-35 recently diagnosed with type 1 diabetes (搜索) for a clinical trial testing CNP-103, an investigational drug developed by COUR Pharmaceuticals (搜索).
The drug targets T cells (搜索) that mistakenly attack pancreatic insulin-producing cells (搜索), aiming to neutralize these immune cells and potentially extend insulin function for years.
The placebo-controlled study involves 10 visits over 13 months with IV infusions, primarily evaluating safety and tolerability while monitoring the drug's ability to preserve natural insulin production.
Researchers at UW Medicine (搜索) in Seattle are recruiting adults recently diagnosed with type 1 diabetes (搜索) for a clinical trial testing CNP-103, an investigational drug that may protect insulin-producing cells (搜索) from immune system destruction. The study represents one of 31 U.S. trial locations examining whether this novel therapy can preserve the body's natural insulin production capability.
Targeting Immune System Dysfunction
CNP-103, developed by Illinois-based COUR Pharmaceuticals (搜索), specifically targets T cells (搜索) that mistakenly attack pancreatic insulin-producing cells (搜索). "The drug targets T cells, immune cells, that are mistakenly attacking the pancreas. By neutralizing these T cells, the drug aims to protect the insulin-producing cells and potentially extend their function for years beyond what would normally happen," explained Dr. Irl Hirsch, diabetes expert and professor of medicine at the University of Washington School of Medicine (搜索).
Dr. Hirsch serves as the lead investigator at UW Medicine (搜索)'s South Lake Union trial site, where researchers hope to recruit six to eight participants over the next six months.
Study Design and Eligibility
The placebo-controlled, double-blind study requires participants to be adults ages 18 to 35 with a type 1 diabetes (搜索) diagnosis within six months. Eligible participants must currently take insulin only with no other diabetes medications, still produce some of their own insulin as confirmed through pre-enrollment screening, have no other significant medical problems, and live in western Washington.
Participation involves 10 total visits over a 13-month study span, including 28 days for screening, 90 days for treatment, and 275 days of follow-up. At least three visits will include an infusion of the test drug or placebo delivered through an IV, with a later phase potentially involving additional infusions. Participants receive a $100 stipend per visit, totaling $1,000 for completing all visits.
Safety Monitoring and Primary Objectives
At this stage, researchers are primarily evaluating CNP-103's safety and tolerability. The main safety consideration is hypoglycemia (搜索), particularly if the drug achieves its intended effect and participants' bodies begin producing more insulin. "The main safety consideration for CNP-103 is low blood sugar, or hypoglycemia, especially if the drug is having its intended effect and a participant's body begins to produce more insulin," Hirsch noted.
All participants will use continuous glucose monitors and provide weekly glucose measures to the research team, allowing insulin dosages to be adjusted as needed. A secondary goal involves understanding whether the drug helps preserve natural insulin production by slowing the immune system's attack on pancreatic cells (搜索).
Growing Adult Disease Burden
Type 1 diabetes (搜索) affects approximately 8.4 million people worldwide, with upward of 65,000 people diagnosed annually in the United States. The demographic profile has shifted significantly over the past half-century. Previously called "juvenile diabetes" due to its rarity in adults, about half of diagnosed patients in the U.S. are now adults, with an average age of 24.
The condition requires vigilant glucose and dietary monitoring to ensure adequate insulin intake through pumps or injections. This 24/7 monitoring and accompanying lifestyle restrictions can cause anxiety, exhaustion, and depression. Chronically high blood sugar can seriously damage kidneys, nervous and cardiovascular systems, and vision, while also affecting patients' and families' finances.
By preserving the body's ability to make its own insulin, the investigational therapy delivered via IV might reduce these long-term disease effects, according to Dr. Hirsch.